RhumbLine Advisers
NERV icon

RhumbLine Advisers’s Minerva Neurosciences NERV Stock Holding History

RhumbLine Advisers’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-5,219
Closed -$122K – 3069
2021
Q1 		$122K Hold
5,219
– – ﹤0.01% 2913
2020
Q4 		$98K Buy
5,219
+337
+7% +$8.49K ﹤0.01% 2969
2020
Q3 		$124K Sell
4,882
-564
-10% -$15.2K ﹤0.01% 2827
2020
Q2 		$157K Buy
5,446
+238
+5% +$14K ﹤0.01% 2851
2020
Q1 		$251K Hold
5,208
– – ﹤0.01% 2482
2019
Q4 		$296K Buy
5,208
+130
+3% +$5.73K ﹤0.01% 2594
2019
Q3 		$315K Buy
5,078
+45
+0.9% +$2.55K ﹤0.01% 2556
2019
Q2 		$227K Buy
5,033
+30
+0.6% +$1.5K ﹤0.01% 2739
2019
Q1 		$315K Sell
5,003
-111
-2% -$6.67K ﹤0.01% 2523
2018
Q4 		$276K Buy
5,114
+1,667
+48% +$122K ﹤0.01% 2581
2018
Q3 		$346K Sell
3,447
-210
-6% -$15.8K ﹤0.01% 2448
2018
Q2 		$241K Buy
3,657
+760
+26% +$46.2K ﹤0.01% 2646
2018
Q1 		$145K Sell
2,897
-21
-0.7% -$1.01K ﹤0.01% 2677
2017
Q4 		$141K Sell
2,918
-554
-16% -$27.5K ﹤0.01% 2723
2017
Q3 		$211K Buy
3,472
+87
+3% +$4.99K ﹤0.01% 2708
2017
Q2 		$240K Buy
3,385
+893
+36% +$57.8K ﹤0.01% 2668
2017
Q1 		$161K Buy
2,492
+99
+4% +$7.69K ﹤0.01% 2707
2016
Q4 		$225K Buy
2,393
+241
+11% +$24.6K ﹤0.01% 2628
2016
Q3 		$243K Buy
2,152
+197
+10% +$19.1K ﹤0.01% 2585
2016
Q2 		$160K Buy
+1,955
New +$124K ﹤0.01% 2821

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RhumbLine Advisers's NERV Position: Q2 2021 in Review

RhumbLine Advisers sold out of Minerva Neurosciences (NERV) in Q2 2021, closing a stake of 5,219 shares — an estimated $122K sold.

RhumbLine Advisers first reported a position in NERV in Q2 2016 and held it in 20 quarters. The position peaked at $346K in Q3 2018. 68 funds tracked by Wall St. Rank hold NERV as of Q2 2021.

  • RhumbLine Advisers reported no remaining Minerva Neurosciences position as of Q2 2021 after selling out during the quarter.
  • RhumbLine Advisers sold 5,219 Minerva Neurosciences shares in Q2 2021, an estimated $122K.
  • RhumbLine Advisers first reported a position in Minerva Neurosciences in Q2 2016 and held it in 20 quarters.
  • RhumbLine Advisers's Minerva Neurosciences position peaked at $346K in Q3 2018.
  • 68 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q2 2021.

Based on RhumbLine Advisers's 13F filing for Q2 2021, filed 5 Aug 2021.